Stereotaxis STXS Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Boston ScientificBSX

-$30M-700%

Merit Medical SystemsMMSI

——

IAR

Integra LifeSciencesIART

——

TFX

TeleflexTFX

——

Other financials

Income statement

See full

Revenue$6.3M-15.8%

Gross profit$3.8M-6.6%

Operating income-$6.0M-0.9%

Net income-$5.9M-0.7%

EPS (diluted)-$0.06+14.3%

Balance sheet

See full

Cash & equivalents$14.6M+36.7%

Total debt$5.3M-10.0%

Total equity$14.4M+399%

Total assets$54.0M+18.2%

Cash flow

See full

Operating cash flow-$3.4M-93.5%

CapEx$79.0K—

Free cash flow-$3.5M—

Valuation

See full

Market cap$168.11M-11.6%

Enterprise value$158.77M-15.9%

P/S5.4×-0.6×

Profitability

See full

Gross margin53.9%+0.5pp

Operating margin-71%-14.0pp

Net margin-69.5%-13.7pp

FCF margin-35.5%-2.4pp

Returns & leverage

See full

Return on equity-251.5%-29.9pp

Debt / equity0.4×-1.7×

Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stereotaxis's contingent consideration fair value adjustments?: Stereotaxis (STXS) reported contingent consideration fair value adjustments of $756K in Q1 2026.
How has Stereotaxis's contingent consideration fair value adjustments changed year-over-year?: Stereotaxis's contingent consideration fair value adjustments increased by 50.6% year-over-year, from $502K to $756K.